银屑病生物制剂临床应用研究进展  

The Advances of Biologic Agents in Psoriasis'Clinical Application

作　　者：贾文斌 牟星宜 周艳[1] 王丽娟[1] 葛睿 牟宽厚[1] JIA Wenbin;MU Xingyi;ZHOU Yan;WANG Lijuan;GE Rui;MU Kuanhou(Department of Dermatology&STD,TheFirst Affiliated Hospital of Xian Jiaotong University,Xi'an,710061,China)

机构地区：[1]西安交通大学第一附属医院皮肤与性病科,陕西西安710061

出　　处：《皮肤科学通报》2020年第5期549-554,M0009,共7页Dermatology Bulletin

摘　　要：银屑病(Psoriasis)是免疫介导的多基因遗传性皮肤病,多种环境因素可以诱导银屑病的发生,随着研究的深入,银屑病也被认为是一种系统性疾病,患者同时伴发代谢综合征、银屑病性关节炎和心血管疾病的风险明显增加。近年来银屑病治疗伴随着生物制剂的问世,治疗的疗效和预后得到了明显的提升,特别是进入2019年,银屑病新型治疗靶点白介素17(Interleukin-17 antagonist,IL-17)和白介素23(Interleu-kin-23 antagonist,IL-23)相继在我国应用于银屑病的临床治疗,银屑病生物制剂家族的成员不断增多,给患者带来治疗手段增加的好处,同时也为临床医生的选择提出了更大的挑战,尤其是对于特殊人群的治疗选择存在较大难度。本文即将目前在国内上市并应用于临床的银屑病生物制剂及其选择原则做一综述,以期为临床医生提供帮助。[Abstract]Psoriasis is an immune-mediated polygenie inheritance cutaneous disease,which can be caused by many factors.With the advances of research,psoriasis is also considered to be a systemic disease in clinic,psoriasis patients have a significantly increased incidence of complicating metabolie sy ndrome,psoriatic arthritis,and cardiovascular disease.The advent of biological agents has significanly improved the therapeutic.effect and prognosis of patients with psoriasis in recent years.In 2019,the new psoriasis therapeutic targets(interleukin-l 7 antagonists and interleukin-23 antagonists)have been approved for clinical application in China.With the increasing variety of biologics for psoriasis,the psoriasis patients have more choice in clinic,at the same time,it also poses greater challenges for the dermatologists.It is a challenge for dermatologists to find the best treatment plan for the special population with psoriasis.With the summarized and applied the description and experience of psoriasis biologics in clinic,we could provide some tips for dermatologists.

关 键 词：银屑病 肿瘤坏死因子拮抗剂 白介素17A拮抗剂 白介素23拮抗剂 

分 类 号：R917[医药卫生—药物分析学]